The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
DDDr. Dereck Mush, MD, MBA
Jul 16
Bayer
Global life sciences company developing medicines across cardiology, nephrology, oncology and women's health.
What they do
Bayer develops prescription medicines and consumer health products. Its non-steroidal mineralocorticoid receptor antagonist finerenone reduced urine albumin-to-creatinine ratio by 25% versus placebo in the Phase 3 FINE-ONE trial for adults with type 1 diabetes and chronic kidney disease. That indication remains investigational.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Cardiorenal medicines
- Product type
- Service
- Stage
- Public
- Headquarters
- Leverkusen, Germany
- Region
- Europe
- Founded
- 1863
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
Related on The Signal
The 33-Year Nephrology Reversal: Inside Kerendia's Type 1 Diabetes Expansion
DDDr. Dereck Mush, MD, MBA
Sep 18
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
DDDr. Dereck Mush, MD, MBA
Jun 5
The senolytic drug pipeline is narrowing toward a smaller set of credible candidates
DDDr. Dereck Mush, MD, MBA
Apr 14